REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07 11 2024 15:05:02 提供 Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

05 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

19 9 2024 15:05:00 提供 Nasdaq GlobeNewswire

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

09 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

27 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

05 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

31 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

27 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

24 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

13 6 2024 22:30:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

13 6 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rezolute to Participate in the Jefferies Global Healthcare Conference

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

21 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

15 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

24 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

23 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

14 12 2023 07:00:00 提供 Nasdaq GlobeNewswire